{
    "id": 19005,
    "cites": 110,
    "cited_by": 0,
    "reference": [
        "Abaluck, J., and Gruber, J. (2011), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Choice Inconsistencies Among the Elderly: Evidence from Plan Choice in the Medicare Part D Program,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 101(4): 1180-1210.",
        "Abbring, J.H., P.A. Chiappori, J.J. Heckman, and J. Pinquet. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Adverse Selection and Moral Hazard: Can Dynamic Data Help to Distinguish?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the European Economic Association 1(2-3): 512-521.",
        "Adams, C.P., and V.V. Brantner. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the Cost of New Drug Development: Is It Really $802 Million?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 25(2): 420-428.",
        "Akerlof, G.A. 1970. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Market for \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Lemons\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d: Quality Uncertainty and the Market Mechanism.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 84(3): 488-500.",
        "Arrow, K.J. 1963. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Uncertainty and the Welfare Economics of Medical Care,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 53(5): 942-973.",
        "Baily, M.N. 1972. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Research and Development Costs and Returns: The U.S. Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 80(1): 70-85.",
        "Bakke, O.M., W.M. Wardell, and L. Lasagna. 1984. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of Safety.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology & Therapeutics 35(5): 559-567.",
        "Bakke, O.M., M. Manocchia, F. de Abajo, K.I. Kaitin, and L. Lasagna. 1995. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Safety Discontinuations in the United Kingdon, the United States, and Spain from 1974 Through 1993: A Regulatory Perspective.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology & Therapeutics 58: 108-117.",
        "Bekelman, J.E., Y. Li, and C.P. Gross. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Scope and Impact of Financial Conflicts of Interest in Biomedical Research - A Systematic Review.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association 289(4): 454-65.",
        "Berndt, E.R., A.H.B. Gottschalk, T.J. Philipson, and M.W. Strobeck. 2005a. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy 8: Article 2.",
        "Berndt, Ernst R., A.H.B. Gottschalk, T.J. Philipson, and M.W. Strobeck. 2005b. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Industry Funding of the FDA: Effects of PDUFA on Approval Times and Withdrawal Rates.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Nature Reviews Drug Discovery 4(7): 545-554.",
        "Cardon, J.H., and I. Hendel. 2001. \"Asymmetric Information in Health Insurance: Evidence from the National Medical Expenditure Survey.\" RAND Journal of Economics 32(3): 408-27.",
        "Carpenter, D., M. Chernew, D.G. Smith. and A.M. Fendrick. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs hlthaff.w3.618. Available at http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w3.618v1.",
        "Carpenter, D., E.J. Zucker, and J. Avorn.. 2008b. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Review Deadlines and Safety Problems: Author\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Reply.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine 359(1): 96-98.",
        "Cawley, J. and T.J. Philipson. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Empirical Examination of Information Barriers to Trade in Insurance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 89(4): 827-846.",
        "Center for Drug Evaluation and Research. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00932003 Report to the Nation: Improving Public Health through Human Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d US Dept. of Health and Human Services, Food and Drug Administration.",
        "Chandra, A., J. Gruber, and R. McKnight. 2010. \"Patient Cost-Sharing and Hospitalization Offsets in the Elderly.\" American Economic Review, 100(1): 193\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c213.",
        "Chernew, M.E., and Fendrick, A.M. (2008), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Value and Increased Cost Sharing in the American Health Care System,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Services Research 43(2): 251-7.",
        "Chiappori, P.-A., and B. Salani\u00c3\u0083\u00c2\u00a9. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Testing for Asymmetric Information in Insurance Markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 108(1): 56-78.",
        "Cohen, A. 2005. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Asymmetric Information and Learning in the Automobile Insurance Market.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics 87(2): 197-207.",
        "Cohen, A. and P. Siegelman. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Testing for Adverse Selection in Insurance Markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Insurance 77(1): 39-84.",
        "CBO. Jan 2008. Technological Change and the Growth of Health Care Spending.",
        "Connolly, M.P., G. Griesinger, W. Ledger, and M.J. Postma. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Impact of Introducing Patient Copayments in Germany on the Use of IVF and ICSI: A Price-elasticity of Demand Assessment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Human Reproduction 24(11): 2796-2800.",
        "Cook, P.J., and D.A. Graham. 1976. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Demand for Insurance and Protection: The Case of Irreplaceable Commodities.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 91(1): 143-156.",
        "Cutler, D.M., and M. McClellan. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Is Technological Change in Medicine Worth It?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 20(5): 11-29.",
        "Cutler, D.M., and S.J. Reber. 1996. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Paying for Health Insurance: The Trade-off Between Competition and Adverse Selection.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 113(2): 433-466.",
        "DiMasi, J.A., and H.G. Grabowski. 2010. [Handbook chapter.] Dimasi, J.A., N.R. Bryant and L. Lasagna. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093New Drug Development in the United-States from 1963 to 1990.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology & Therapeutics 50(5): 471-86.",
        "Dimasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Innovation: New Estimates of Drug Development Costs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 22(2): 151-185.",
        "Dionne, G. 1982. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Moral Hazard and State-dependent Utility Function.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Insurance 49(3): 405-422.",
        "Dionne, G., C. Gourileroux, and C. Vanasse (2001). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Testing for Evidence of Adverse Selection in the Automobile Insurance Market: A Comment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 109 (2): 444-453.",
        "Fang, H., M. P. Keane, and D. Silverman. 2008. \"Sources of Advantageous Selection: Evidence from the Medigap Insurance Market.\" Journal of Political Economy 116(2): 303-350.",
        "Finkelstein, A. (2004), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119(2): 527-564.",
        "Finkelstein, A. (2007), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Aggregate Effects of Health Insurance: Evidence from the Introduction of Medicare,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 122(1): 1-37.",
        "Finkelstein, A. and K. McGarry. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Multiple Dimensions of Private Information: Evidence from the Long Term Care Insurance Market.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 96(4): 938-58.",
        "Finkelstein, A., and J. Poterba. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Adverse Selection in Insurance Markets: Policyholder Evidence from the U.K. Annuity Market.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 112(1): 183-208.",
        "Frank, R. (2007), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Behavior Economics and Health Economics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in P. Diamond and H. Vartiainen (eds.,), Behavior Economics and its Applications, Princeton University Press: Princeton, NJ.",
        "Frank, R. and Lamiraud, K. (2009), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Choice, Price Competition, and Complexity in Markets for Health Insurance,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Behavior and Organization 71(2): 550-562.",
        "Friedman, M. A., et al. 1999. The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is A Problem?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association 281: 1728-1734.",
        "Gaynor, M., J. B. Rebitzer, and L. J. Taylor, 2004. \"Physician Incentives in Health Maintenance Organizations.\" Journal of Political Economy 112(4): 915-931.",
        "General Accounting Office. 2002. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities.",
        "Goldman, D., G. Joyce, and Y. Zheng (2007). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association 298, 61-69.",
        "Goldman, D., and T., Philipson (2007), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Integrated Insurance Design with Multiple Medical Technologies\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d , American Economic Review, March.",
        "Grabowski, H.G., J.M. Vernon, and L.G. Thomas. 1978. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the Effect of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 21(1): 133-163.",
        "Gruber, J., and Poterba, J. (1994), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Tax Incentives and the Decision to Purchase Health Insurance: Evidence from the Self-Employed,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 109(3): 701-33.",
        "Hansen, R.W. 1979. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Pharmaceutical Development Process: Estimates of Current Development Costs and Times and the Effects of Regulatory Changes.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d In Issues in Pharmaceutical Economics, ed. R.I. Chien, 151-87. Lexington, MA: Lexington Books.",
        "He, D. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Life Insurance Market: Asymmetric Information Revisited.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 93(9-10): 1090-1097.",
        "Helland, E., D. Lakdawalla, A. Malani, and S. Seabury. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Tort Liability on the Market for Prescription Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper.",
        "Hendel, I., and A. Lizzeri. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Role of Commitment in Dynamic Contracts: Evidence from Life Insurance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 188(1): 299-327.",
        "Himmelstein, D.U., D. Thorne, E. Warren, and S. Woolhandler. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Bankruptcy in the United States, 2007: Results from a National Study.\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093 The American Journal of Medicine 122: 741-746.",
        "Hult, K., and T. Philipson (2012), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Care Reforms and The Value of Future Public Liabilities\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, NBER WP.",
        "Hutt, P.B., R.A. Merrill, and L.A. Grossman. 2007. Food and Drug Law: Cases and Materials, Third Edition. NY: Foundation Press.",
        "Jensen, E.J. 1987. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Research Expenditures and the Discovery of New Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Industrial Economics 36(1): 83-95.",
        "Kaitin, K., P. DiCerbo, et al. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The new drug approvals of 1987, 1988, and 1989: trends in drug development.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Journal of Clinical Pharmacology 31(2): 116-122.",
        "Keeler, E.B., and J.E. Rolph. 1989. \"The Demand for Episodes of Treatment in the Health Insurance Experiment. \" Journal of Health Economics 7: 337-367.",
        "Kniesner, T.J., Viscusi, W.K., C. Woock, and J.P. Ziliak. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of a Statistical Life: Evidence from Panel Data.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics 94(1): 74-87.",
        "Kolstad, C.D., T.S. Ulen, and G.V. Johnson. 1990. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ex Post Liability for Harm vs. Ex Ante Safety Regulation: Substitutes or Complements?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 80(4): 888-901.",
        "Kondo, M., S. Hoshi, and I. Okubo. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Does Subsidy Work? Price Elasticity of Demand for Influenza Vaccination Among Elderly in Japan.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Policy 91(3): 269-276.",
        "Krueger, A.B., and I. Kuziemko (2013), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Demand for Health Insurance Among Uninsured Americans: Results of a Survey Experiment and Implications for Policy,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, forthcoming Lakdawalla, D., T. Philipson, and Y.R. Wang. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Intellectual Property and Marketing.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research Working Paper 12577.",
        "Lakdawalla, D., and N. Sood. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Innovation and the Welfare Effects of Public Drug Insurance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 93(3-4):541-548.",
        "Lakdawalla, D., and N.Sood. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Insurance as a Two-Part Pricing Contract.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research Working Paper 12681.",
        "Lichtenberg, F. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Innovation, Mortality Reduction, and Economic Growth.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d In Measuring the Gains from Medical Research: An Economic Approach, eds. K.M. Murphy and R.H. Topel,.74-109. Chicago: University of Chicago Press.",
        "Malani, A., and T. Philipson (2012), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Regulation of Medical Products\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, in Handbook of The Economics of the Biopharmaceutical Sector, edited by P. Danzon and S. Nicholson, Oxford university Press.",
        "Malani, A., O. Benbom, and M. van der Laan. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Accounting for Differences Among Patients in the FDA Approval Process.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper.",
        "Manning, R.L. 1994. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Changing Rules in Tort Law and the Market for Childhood Vaccines.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law & Economics 37(1): 247-275.",
        "Manning, R.L. 1997. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Products Liability and Prescription Drug Prices in Canada and the United States.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law & Economics 40: 203-243.",
        "Manning, W.G., J.P. Newhouse, N. Duan, E.B. Keeler, A. Leibowitz, and M.S. Marquis. 1987. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 77(3): 251-77.",
        "May, M.S., W.M. Wardell, and L. Lasagna. 1983. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093New Drug Development During and After a Period of Regulatory Change: Clinical Research Activity of Major United States Pharmaceutical Firms, 1958-1979.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology and Therapeutics 33(6): 691-700.",
        "McCarthy, D., and O.S. Mitchell. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093International Adverse Selection in Life Insurance and Annuities,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in S. Tuljapurkar, N. Ogawa, and A.H. Gauthier (eds.), Ageing in Advanced Industrial States: Riding the Age Waves, Vol. 3, Springer, 119-135.",
        "McGuire, T.G. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Demand for Health Insurance,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Handbook of Health Economics Vol. 2, edited by M.V. Pauly, T.G. McGuire, and P.P. Barros. Elsevier.",
        "McGuire, T.G., R. Nelson, and T. Spavins. 1975. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments: A Comment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 83(3): 655-662.",
        "Muermann, A. and D. Straka. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Asymmetric Information in Automobile Insurance: New Evidence from Telematic Data,\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093 working paper.",
        "Mulligan, C., and T.J. Philipson. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurance Market Participation under Symmetric Information,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d working paper.",
        "Mund, V.F. 1970. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Return on Investment of the Innovative Pharmaceutical Firm.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d In The Economics of Drug Innovation, ed. J.D. Cooper, 125-138. American University, Washington, DC.",
        "Murphy, Kevin M. and Robert H. Topel. 2003. Measuring the Gains from Medical Research: An Economic Approach. Chicago: University of Chicago Press.",
        "Musgrave, R.A. 1959. The Theory of Public Finance. New York: McGraw Hill.",
        "Nardinelli, C., M. Lanthier, and R. Temple. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Review Deadlines and Safety Problems.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine 359(1): 95-96.",
        "Newhouse, J. 1992. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Care Costs: How Much Welfare Loss?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Perspectives 6(3): 3-21.",
        "Nyman, J.A. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Health Insurance: The Access Motive,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 18(2): 141-52.",
        "Olson, M.K. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Explaining Reductions in FDA Drug Review Times: PDUFA Matters.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs http://content.healthaffairs.org/cgi/content/full/hlthaff.w4.s1v1/DC1.",
        "Oster E., I. Shoulson, K.A. Quaid, and E.R. Dorsey. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Genetic Adverse Selection: Evidence from LongTerm Care Insurance and Huntington\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Disease.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 94: 1041-1050.",
        "Pauly, M.V. 1968. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Economics of Moral Hazard: Comment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 58(3): 531537.",
        "Pauly, M.V. 1990. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Rational Nonpurchase of Long Term Care Insurance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 98(1): 153-168.",
        "Peltzman, S. 1973a. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Evaluation of Consumer Safety Protection Legislation: the 1962 Drug Amendments.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 81(5): 1049-1091.",
        "Peltzman, S. 1975. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Evaluation of Consumer Product Legislation: The 1962 Drug Amendments: A Reply.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 83(3): 663-667.",
        "Philipson, T.J., E.R. Berndt, A.H.B. Gottschalk, and E. Sun. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 92: 1306-1325.",
        "Philipson, T.J., and E. Sun. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Is the Food and Drug Administration Safe and Effective?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Perspectives 22(1): 85-102.",
        "Philipson, T.J., E. Sun, and D. Goldman. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effects of Product Liability Exemption in the Presence of the FDA.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper.",
        "Philipson, T., Sun, E. Sun, A. Jena, and D. Goldman. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Re-examination of the Costs of Medical R&D\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Working paper.",
        "Polinsky, A. M. and S. Shavell. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Uneasy Case for Product Liability.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Law Review. 123(6): 1437-92.",
        "Richaudeau, D. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Automobile insurance contracts and risk of accident: an empirical test using French individual data.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Geneva Papers on Risk and Insurance - Theory 24 (1): 97-114.",
        "Rothschild, M. and J. Stiglitz. 1976. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 90(4): 629-49.",
        "Saito, K. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Testing for Asymmetric Information in the Automobile Insurance Market Under Rate Regulation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Insurance 73(2): 335-356 Sarett, L.H. 1974. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093FDA Regulations and Their Influence on Future Research and Development.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Research Management 17(2): 18-20.",
        "Schnee, J.E. 1972. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Development Costs: Determinants and Overruns.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Business 45(3): 347374.",
        "Shavell, S. 1984a. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Liability for Harm versus Regulation of Safety.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Legal Studies 13(2): 357374.",
        "Shavell, S. 1984b. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Model of the Optimal Use of Liability and Safety Regulation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics 15(2): 271-280.",
        "Strombom, B.A., T.C. Buchmueller, and P.J. Feldstein (2002), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Switching Costs, Price Sensitivity and Health Plan Choice,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 21(1): 89-116.",
        "Tabarrok, A.T. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Assessing the FDA via the Anomaly of Off-Label Drug Prescribing.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Independent Review 5(1): 25-53.",
        "Thomas, L.G. 1990. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulaton and Firm Size: FDA Impacts on Innovation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics 21(4): 497-517.",
        "Vernon, J.A. J.H. Golec, R. Lutter, and C. Nardinelli. 2009. An Exploratory Study of FDA New Drug Review Times, Prescription Drug User Fee Acts, and R&D Spending. Quarterly Review of Economics and Finance 49: 1260-1274.",
        "Viscusi, W.K., and J.E. Aldy. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of a Statistical Life: A Critical Review of Market Estimates from Around the World.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Risk and Uncertainty 27(1): 5-76.",
        "Viscusi, W.K. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093What\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s to Know? Puzzles in the Literature on the Value of a Statistical Life.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Surveys 26(5): 763-768.",
        "Wardell, W. 1973. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Introduction of New Therapeutic Drugs in The United States and Great Britain: An International Comparison.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Pharmacology and Therapeutics 14(5):773-90.",
        "Washington Legal Foundation v. Henney, 56 F. Supp.2d 81 (D.D.C. 1999).",
        "Weitzman, M.L. 1974. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prices vs. Quantities.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economic Studies 41(4): 477-491.",
        "Wiggins, S.N. 1981. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics 63(4): 615-619.",
        "Wiggins, S.N. 1983. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Impact of Regulation on Pharmaceutical Research Expenditures: A Dynamic Approach.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Economic Inquiry 21(1): 115-128.",
        "Wittman, D. 1977. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prior Regulation versus Post Liability: The Choice between Input and Output Monitoring.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Legal Studies 6(1): 193-211.",
        "Wolfe, J.R., and J.H. Goddeeris. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Adverse Selection, Moral Hazard, and Wealth Effects in the Medigap Insurance Market.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 10: 433-459.",
        "Zeckhauser, R.J. 1970. \"Medical Insurance: A Case Study of the Tradeoff between Risk Spreading and Appropriate Incentives.\" Journal of Economic Theory 2(1): 10-26.",
        "Zeckhauser, R.J. 1973. \"Coverage for Catastrophic Illness.\" Public Policy 21(2): 149-72."
    ]
}